Therefore, in acute myeloid leukemia cells (and possibly other cancer cells), the interaction of BCAA metabolism with that of the GLS1 and GTωA pathways results in fine-tuning of the levels of α-ketoglutarate needed for cancer progression via increased BCAA metabolism. The gene discussed is GLS; the disease is cancer.